Lenalidomide for the treatment of B-cell lymphoma. - Test2 - elhamkhani - TriplyDB

Lenalidomide for the treatment of B-cell lymphoma.

Lenalidomide for the treatment of B-cell lymphoma.

http://www.wikidata.org/entity/Q30249007

about

Complete response of age-related Epstein-Barr virus-associated polymorphic nodal lymphoproliferative disease of plasmacytic type to low-dose lenalidomide.

P2860

Q45325811-AD29ECF8-A98A-4FB7-8E17-C602C3A91178

P2860

Lenalidomide for the treatment of B-cell lymphoma.

http://www.wikidata.org/entity/Q30249007

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Lenalidomide for the treatment of B-cell lymphoma.

@ast

Lenalidomide for the treatment of B-cell lymphoma.

@en

type

label

Lenalidomide for the treatment of B-cell lymphoma.

@ast

Lenalidomide for the treatment of B-cell lymphoma.

@en

prefLabel

Lenalidomide for the treatment of B-cell lymphoma.

@ast

Lenalidomide for the treatment of B-cell lymphoma.

@en

P1433

Q30249007-58DFDB94-C9D9-4AB0-98E6-08D007B25AD4

P1476

Q30249007-A4C7EFD9-752F-47E2-8DAC-FACBE141F7AC

P2093

Q30249007-2808309A-EC1F-4866-8EB2-4393867A2797

Q30249007-2BF94B46-59EE-4937-A9D8-62F6255D3E2A

Q30249007-B85B851A-E782-473A-A153-A5610AE2859A

Q30249007-D5D6E2E2-3E22-4A79-9DAE-753124988C6A

P2860

Q30249007-0094667A-D2F4-45CB-9F8B-09A3698CFD5D

Q30249007-05C46168-4616-45FB-8BC0-43CC8F2F96AB

Q30249007-071DE867-3435-4973-B5A8-4552A542DF7F

Q30249007-0B085AD5-0F22-4182-BD8D-10067CF78D29

Q30249007-0BAADAFE-3BD0-4CA7-81CF-9E4F64C9F322

Q30249007-0E650009-50D4-4ED3-AC0F-8A9DF1261109

Q30249007-1012C053-CC97-40CB-B112-A62C2432094E

Q30249007-11F9254C-47B9-4EE9-B29A-2E381700E154

Q30249007-1854A71A-1399-44F3-B1E7-F2B5DC50DF08

Q30249007-1AA322CA-45D4-46B7-AC7F-C1AAED5B9CB5

P304

Q30249007-44DB2133-C0CE-4465-850E-C3803AA61BAD

P31

Q30249007-A3435FCC-00F1-4BF3-91D8-0436D77A787E

P356

Q30249007-0432D15C-963A-4E97-86D0-F649F38DD82B

P407

Q30249007-8526BE81-B52E-473A-A33E-6F32BFD718BA

P433

Q30249007-178F3DF4-B8EC-418C-B8A2-CFEC1CE20486

P478

Q30249007-913E4B3A-EB6E-4961-836B-661697B0295F

P577

Q30249007-7138CC8F-9D99-46BE-BD88-019C1B4DBE4F

P698

Q30249007-BAC6060C-BF61-4EDA-BEED-00EA8CA9FF96

P356

13543784.2016.1208170

P1433

Expert Opinion on Investigational Drugs

P1476

Lenalidomide for the treatment of B-cell lymphoma.

@en

P2093

Diane Coso

http://www.w3.org/2001/XMLSchema#string

Jean-Marc Schiano de Colella

http://www.w3.org/2001/XMLSchema#string

Réda Bouabdallah

http://www.w3.org/2001/XMLSchema#string

Sylvain Garciaz

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

P304

1103-1116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543784.2016.1208170

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27414850

http://www.w3.org/2001/XMLSchema#string